Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2423studies indexed1086with human data145registered trials2091carry a numeric findingLibrarian added 0 studies today

Showing 6 studiesSortNewest indexed ▾

grade

Perioperative Administration of Efgartigimod in myasthenia gravis patients with Thymoma: A six-case series.

Efpeglenatide · Journal of neuroimmunology · 2026 · Observational · n=6

Efgartigimod may improve perioperative outcomes in gMG patients with thymoma, but further studies are needed to confirm these findings.

Not reported in abstract.

summary

Full text read

Source →

grade

Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.

Efpeglenatide · Platelets · 2026 · Case report · n=1

Efgartigimod may induce a partial response in refractory ITP, which can be enhanced by TPO-RAs, leading to sustained remission.

Not reported in abstract.

summary

Full text read

Source →

grade

Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy.

Efpeglenatide · Journal of medical economics · 2026 · Observational

Panzyga treatment pathways were associated with lower total treatment costs and cost per responder compared to Vyvgart hytrulo at both 6 and 12 months.

$124,812 total treatment cost for Panzyga 1 g/kg at 6 months.

summary

Full text read

Source →

grade

Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.

Efpeglenatide · Circulation · 2023 · RCTHigh-impact journal

The study suggests that higher doses of efpeglenatide may lead to better cardiovascular outcomes, but the clinical significance of lower doses remains uncertain.

MACE occurred in 125 (9.2%) participants assigned to placebo, 84 (6.2%) participants assigned to 6 mg of efpeglenatide, HR 0.65 (95% CI, 0.5-0.86), P=0.0027.

summary

Full text read

Source →

grade

The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.

Efpeglenatide · Diabetes, obesity & metabolism · 2026 · Meta-analysisHigh-impact journal

GLP-1-based therapies appear to have a favorable cardiovascular profile in adults with Type 2 diabetes, but not all comparisons showed statistically significant benefits.

Not reported in abstract.

summary

Full text read

Source →

grade

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.

Efpeglenatide · Diabetes, obesity & metabolism · 2026 · ObservationalHigh-impact journal

Changes in LDL cholesterol and UACR may explain some of efpeglenatide's effect on reducing major cardiovascular events, but the contributions are modest.

27% reduction in major cardiovascular events compared to placebo during a median follow-up of 1.81 years, n=4076.

summary

Full text read

Source →

Showing 6 of 6